Document is current
Any future updates will be listed below
-
Authors
Afshar-Bakshloo, Melissa
Albers, Sarah
Richter, Chiara
Berninger, Ottilia
Blohmer, Jens-Uwe
Roehle, Robert
Speiser, Dorothee
Karsten, Maria Margarete
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 4 May 2023
Accepted: 12 July 2023
First Online: 28 July 2023
Declarations
:
: The study was approved by the institutional Charité – Universitätsmedizin Berlin ethics committee (EA 4/127/16 08/30/2016) and performed in accordance with the Declaration of Helsinki.For patient participation in the study patients provided written informed consent after receiving verbal and written information on the patient-reported outcome program at Charité – Universitätsmedizin Berlin breast center.
: Not applicable.
: OB: Employee and stockholder at Takeda Pharma (financial interests). MMK: Speaker fee from Roche, Gilead, Astra Zeneca, Sysmex (financial interests).MAB, SA, CR, JUB, RR, DS declare that they have no competing interests.
